Page 130 - 南京医科大学学报自然科学版
P. 130
第41卷第12期
·1836 · 南 京 医 科 大 学 学 报 2021年12月
ening cutaneous bleeding in childhood klippel⁃trenaunay et al. Fibroadipose vascular anomaly treated with sirolim⁃
syndrome treated with oral sirolimus[J]. JAMA Dermatol, us:successful outcome in two patients[J]. Pediatr Derma⁃
2016,152(9):1058-1059 tol,2017,34(6):e317-e320
[37] IACOBAS I,BURROWS P E,ADAMS D M,et al. Oral ra⁃ [40] ZUNIGA⁃CASTILLO M,TENG C L,TENG J M C. Genet⁃
pamycin in the treatment of patients with hamartoma syn⁃ ics of vascular malformation and therapeutic implications
dromes and PTEN mutation[J]. Pediatr Blood Cancer, [J]. Curr Opin Pediatr,2019,31(4):498-508
2011,57(2):321-323 [41] CASCORBI I. The pharmacogenetics of immune⁃modulat⁃
[38] GONZÁLEZ⁃HERMOSA M R,GUERRA E,TUDURI I, ing therapy[J]. Adv Pharmacol,2018,83:275-296
et al. Clapo syndrome:effective response to treatment [42] 张 钰,张宏文,杨 劲,等. 肾移植患者西罗莫司的群
with oral rapamycin[J]. Dermatologic Therapy,2019,32 体药代动力学模型研究[J]. 南京医科大学学报(自然
(4):e12991 科学),2017,37(9):1193-1199
[39] ERICKSON J,MCAULIFFE W,BLENNERHASSETT L, [收稿日期] 2021-06-30
(上接第1820页) Invest Ophthalmol Vis Sci,2011,52(7):4605-4609
60-61 [12] MEDEIROS M D,ALKABES M,NAVARRO R,et al.
[4] 许 珂,吴玲玲,马志中,等. 视网膜静脉阻塞患者中原 Dexamethasone intravitreal implant in vitrectomized ver⁃
发性开角型青光眼发病比例的研究[J]. 中华实验眼科 sus nonvitrectomized eyes for treatment of patients with
杂志,2016,34(6):552-557 persistent diabetic macular edema[J]. J Ocul Pharmacol
[5] 雷 杰,胡仔仲,刘庆淮. OCTA 技术在盘周血流改变 Ther,2014,30(9):709-716
中的应用[J]. 南京医科大学学报(自然科学版),2020, [13] ALSHAHRANI S T,DOLZ⁃MARCO R,GALLEGO⁃PIN⁃
40(11):1730-1738 AZO R,et al. Intravitreal dexamethasone implant for the
[6] ROBERTI G,ODDONE F,AGNIFILI L,et al. Steroid⁃in⁃ treatment of refractory macular edema in retinal vascular
duced glaucoma:Epidemiology,pathophysiology,and diseases:results of the KKESH international collaborative
clinical management[J]. Surv Ophthalmol,2020,65(4): retina study group[J]. Retina,2016,36(1):131-136
458-472 [14] BOYER D S,YOON Y H,BELFORT R J,et al. Three⁃
[7] THEODOROPOULOU S,ELLABBAN A A,JOHNSTON year,randomized,sham⁃controlled trial of dexamethasone
R L,et al. Short⁃term safety of dexamethasone implant for intravitreal implant in patients with diabetic macular ede⁃
treatment of macular edema due to retinal vein occlusion, ma[J]. Ophthalmology,2014,121(10):1904-1914
in eyes with glaucoma or treated ocular hypertension[J]. [15] HU Q,LI H,XU W,et al. Comparison between ozurdex
Graefes Arch Clin Exp Ophthalmol,2017,255(4):725- and intravitreal anti ⁃ vascular endothelial growth factor
732 treatment for retinal vein occlusion⁃related macular ede⁃
[8] 中华医学会眼科学分会青光眼学组,中国医师协会眼 ma:a systematic review and meta⁃analysis of randomized
科医师分会青光眼学组.中国青光眼指南(2020 年) controlled trials[J]. Indian J Ophthalmol,2019,67(11):
[J]. 中华眼科杂志,2020,56(8):573-586 1800-1809
[9] KIDDEE W,TROPE G E,SHENG L,et al. Intraocular [16] SHARMA A,KUPPERMANN B D,BANDELLO F,et al.
pressure monitoring post intravitreal steroids:a systemat⁃ Intraocular pressure(IOP)after intravitreal dexametha⁃
ic review[J]. Surv Ophthalmol,2013,58(4):291-310 sone implant(Ozurdex)amongst different geographic pop⁃
[10] CHANG⁃LIN J E,ATTAR M,ACHEAMPONG A A,et al. ulations⁃GEODEX⁃IOP study[J]. Eye(Lond),2020,34
Pharmacokinetics and pharmacodynamics of a sustained⁃ (6):1063-1068
release dexamethasone intravitreal implant[J]. Invest [17] CHOI W,PARK S E,KANG H G,et al. Intraocular pres⁃
Ophthalmol Vis Sci,2011,52(1):80-86 sure change after injection of intravitreal dexamethasone
[11] CHANG⁃LIN J E,BURKE J A,PENG Q,et al. Pharmaco⁃ (Ozurdex)implant in Korean patients[J]. Br J Ophthalmol,
kinetics of a sustained⁃release dexamethasone intravitreal 2019,103(10):1380-1387
implant in vitrectomized and nonvitrectomized eyes[J]. [收稿日期] 2021-06-27